Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07521657 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT07521657 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 55 participants.
The verdict
NCT07521657, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).
Interventions
- DRUG mirdametinib
- COMBINATION_PRODUCT mirdametinib with radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2031-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07521657
The ClinicalTrials.gov registry entry for NCT07521657 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mirdametinib is the first listed.
NCT07521657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07521657 about?
NCT07521657 is a clinical study titled "Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma". This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associat...
What is the current status of trial NCT07521657?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2026-08-01. Estimated completion is 2031-08-01.
What interventions are being tested in trial NCT07521657?
The interventions under investigation include: mirdametinib (DRUG), mirdametinib with radiation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07521657?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.